29 Sep 2022
Normally used to treat cardiovascular disease, the mineralocorticoid antagonist spironolactone has now shown efficacy in decreasing alcohol intake. The study investigated the effects on alcohol consumption in mice, rats and people and is published in Molecular Psychiatry.
Migraines and menopause symptoms linked to cardiovascular disease risk
19 Apr 2024
Risk of postpartum depression associated with stress during adolescence
19 Apr 2024
Surgery for hypoparathyroidism sees reduced facture rates
19 Apr 2024
Patients with type 2 diabetes taking antidepressants have a higher mortality risk
19 Apr 2024
Endocrine-disrupting chemical levels found at alarming levels in Australia
11 Apr 2024